Montelukast altered BDNF and CHRNA7 gene expression were associated with behavioral changes in rats.

<ns3:p>Background Montelukast is a pharmaceutical agent predominantly used for the management of asthma and allergic rhinitis. It fulfils its role by antagonizing the cysteinyl leukotriene receptor type 1, hence inhibiting the effects of inflammatory leukotrienes such as LTD4. Nonetheless, like to other pharmaceuticals, montelukast is associated with possible adverse effects. Prevalent symptoms include cephalalgia, abdominal discomfort, and influenza-like manifestations. In few instances, it has been linked to changes in mood, agitation, and sleep disruptions, particularly in youngsters. Objective to assess the potential psychotropic effects of montelukast by measuring changes in cortisol levels, examining genes involved in neurotransmission and neuroplasticity, and observing behavioral tests in treated animals. Methods Thirty-five albino male rats weighing 150-200 milligrams the rats were categorized into five groups, with seven individuals in each group. Group II received reserpine as the positive control, while montelukast was administered at doses of 5 mg/kg for group III, 10 mg/kg for group IV, and 20 mg/kg for group V. The negative control group I was treated with a solvent combination of DMSO and acetic acid. Results reduction in cortisol levels, downregulation of BDNF and chrna7 genes, and significant alterations in behavioral assessments in the reserpine and montelukast groups in a dose-dependent manner. Conclusion Animals treated with montelukast exhibit significant alterations in behavior and biomarker levels, suggesting potential psychological changes induced by the medication.</ns3:p>